Decrease of elevated intraocular pressure (IOP) in adult patients with open- angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction(see section 5.1).

Posology Use in adults, including the elderly The recommended dose is one drop of SIMBRINZA in the affected eye(s) two times daily. Missed dose If a dose is missed, treatment should be continued with the next dose as planned. Hepatic and/or renal impairment SIMBRINZA has not been studied in patients with hepatic impairment and caution is therefore recommended in this population (see section 4.4). SIMBRINZA has not been studied in patients with severe renal impairment (CrCl <30 mL/min) or in patients with hyperchloraemic acidosis. Since the brinzolamide component of SIMBRINZA and its metabolite are excreted predominantly by the kidney, SIMBRINZA is contraindicated in such patients (see section 4.3). Paediatric population The safety and efficacy of SIMBRINZA in children and adolescents aged 2 to 17 years have not been established. No data are available. SIMBRINZA is contraindicated in neonates and infants aged less than 2 years in the decrease of elevated intraocular pressure (IOP) with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction because of safety concerns (see section 4.3). Method of administration For ocular use. Patients should be instructed to shake the bottle well before use. When nasolacrimal occlusion is used and the eyelids are closed for 2 minutes, systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity (see section 4.4). To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Patients should be instructed to keep the bottle tightly closed when not in use. SIMBRINZA may be used concomitantly with other topical ophthalmic medicinal products to lower intraocular pressure. If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart.

Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1. Hypersensitivity to sulphonamides (see section 4.4). Patients receiving monoamine oxidase (MAO) inhibitor therapy (see section 4.5). Patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin) (see section 4.5). Patients with severe renal impairment (see section 4.4). Patients with hyperchloraemic acidosis. Neonates and infants under the age of 2 years (see section 4.4).

The medicinal product should not be injected. Patients should be instructed not to swallow SIMBRINZA. Ocular effects SIMBRINZA has not been studied in patients with narrow-angle glaucoma and its use is not recommended in these patients. The possible effect of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count). Specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration and wearing contact lenses might increase the risk for the cornea (for further instructions on wearing contact lenses, see below under “Benzalkonium chloride”). Careful monitoring of patients with compromised corneas, such as patients with diabetes mellitus or corneal dystrophies, is recommended. Brimonidine tartrate may cause ocular allergic reactions. If allergic reactions are observed, treatment should be discontinued. Delayed ocular hypersensitivity reactions have been reported with brimonidine tartrate, with some reported to be associated with an increase in IOP. The potential effects following cessation of treatment with SIMBRINZA have not been studied. While the duration of IOP-lowering effect for SIMBRINZA has not been studied, the IOP-lowering effect of brinzolamide is expected to last for 5-7 days. The IOP-lowering effect of brimonidine may be longer. Systemic effects SIMBRINZA contains brinzolamide, a sulphonamide inhibitor of carbonic anhydrase and, although administered topically, is absorbed systemically. The same types of adverse drug reactions that are attributable to sulphonamides may occur with topical administration, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). At the time of prescription, patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs of serious reactions or hypersensitivity occur, SIMBRINZA should be withdrawn immediately . Cardiac disorders Following administration of SIMBRINZA, small decreases in blood pressure were observed in some patients. Caution is advised when using medicinal products such as antihypertensives and/or cardiac glycosides concomitantly with SIMBRINZA or in patients with severe or unstable and uncontrolled cardiovascular disease (see section 4.5). SIMBRINZA should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans. Acid/base disturbances Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. SIMBRINZA contains brinzolamide, an inhibitor of carbonic anhydrase, and although administered topically, is absorbed systemically. The same types of adverse reactions that are attributable to oral carbonic inhibitors (i.e. acid-base disturbances) may occur with topical administration (see section 4.5). SIMBRINZA should be used with caution in patients with risk of renal impairment because of the possible risk of metabolic acidosis. SIMBRINZA is contraindicated in patients with severe renal impairment (see section 4.3). Hepatic impairment SIMBRINZA has not been studied in patients with hepatic impairment; caution should be used in treating such patients (see section 4.2). Mental alertness Oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/or physical coordination in elderly patients. SIMBRINZA is absorbed systemically and this may therefore occur with topical administration (see section 4.7). Paediatric population The safety and efficacy of SIMBRINZA in children and adolescents aged 2 to 17 years have not been established. Symptoms of brimonidine overdose (including loss of consciousness, hypotension, hypotonia, bradycardia, hypothermia, cyanosis and apnoea) have been reported in neonates and infants receiving brimonidine eye drops as part of medical treatment of congenital glaucoma. SIMBRINZA is therefore contraindicated in children below 2 years of age (see section 4.3). Treatment of children 2 years and above (especially those in the 2 7 age range and/or weighing <20 kg) is not recommended because of the potential for central nervous system-related side effects (see section 4.9). Benzalkonium chloride SIMBRINZA contains benzalkonium chloride which may cause eye irritation and is known to discolour soft contact lenses. Contact with soft contact lenses should be avoided. Patients must be instructed to remove contact lens prior to application of SIMBRINZA and wait at least 15 minutes before reinsertion. Benzalkonium chloride has been reported to cause eye irritation and symptoms of dry eyes and may affect the tear film and corneal surface. It should be used with caution in dry eye patients and in patients whose cornea may be compromised. Patients should be monitored in case of prolonged use.

No specific drug

Pregnancy There are no or limited amount of data from the use of SIMBRINZA in pregnant women. Brinzolamide was not teratogenic in rats and rabbits, following systemic administration (oral gavage). Animal studies with oral brimonidine do not indicate direct harmful effects with respect to reproductive toxicity. In animal studies, brimonidine crossed the placenta and entered into the foetal circulation to a limited extent (see section 5.3). SIMBRINZA is not recommended during pregnancy and in women of childbearing potential not using contraception. Breast-feeding It is unknown whether topical SIMBRINZA is excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown that following oral administration, minimal levels of brinzolamide are excreted in breast milk. Brimonidine administered orally is excreted in breast milk. SIMBRINZA should not be used by women who are breast-feeding. Fertility Non-clinical data do not show any effects of brinzolamide or brimonidine on fertility. There are no data on the effect of topical ocular administration of SIMBRINZA on human fertility.

SIMBRINZA has a moderate influence on the ability to drive and use machines. SIMBRINZA may cause dizziness, fatigue and/or drowsiness, which may impair the ability to drive or use machines. Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation the patient must wait until the vision clears before driving or using machines. Oral carbonic anhydrase inhibitors may impair the ability of elderly patients to perform tasks requiring mental alertness and/or physical coordination (see section 4.4).

Summary of the safety profile In clinical trials involving SIMBRINZA dosed twice daily the most common adverse reactions were ocular hyperaemia and ocular allergic type reactions occurring in approximately 6 7% of patients, and dysgeusia (bitter or unusual taste in the mouth following instillation) occurring in approximately 3% of patients. Tabulated summary of adverse reactions The following adverse reactions have been reported during clinical studies with SIMBRINZA twice-daily dosing and during clinical studies and post-marketing surveillance with the individual components brinzolamide and brimonidine. They are classified according to the subsequent convention: very common (=1/10), common (=1/100 to <1/10), uncommon (=1/1,000 to <1/100), rare (=1/10,000 to <1/1,000), very rare (<1/10,000) or not known (cannot be estimated from the available data). Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness. System Organ Classification Adverse reactions Infections and infestations Uncommon: nasopharyngitis2, pharyngitis2, sinusitis2 Not known: rhinitis2 Blood and lymphatic system disorders Uncommon: red blood cells decreased2, blood chloride increased2 Immune system disorders Uncommon: hypersensitivity3 Psychiatric disorders Uncommon: apathy2, depression2,3, depressed mood2, insomnia1, libido decreased2, nightmares2, nervousness2 Nervous system disorders Common: somnolence1, dizziness3, dysgeusia1 Uncommon: headache1, motor dysfunction2, amnesia2, memory impairment2, paraesthesia2 Very rare: syncope3 Not known: tremor2, hypoaesthesia2, ageusia2 Eye disorders Common: eye allergy1, keratitis1, eye pain1, ocular discomfort1, blurred vision1, abnormal vision3, ocular hyperaemia1, conjunctival blanching3 Uncommon: corneal erosion1, corneal oedema2, blepharitis1, corneal deposits (keratic precipitates)1, conjunctival disorder (papillae)1, photophobia1, photopsia2, eye swelling2, eyelid oedema1, conjunctival oedema1, dry eye1, eye discharge1, visual acuity reduced2, lacrimation increased1, pterygium2, erythema of eyelid1, meibomianitis2, diplopia2, glare2, hypoaesthesia eye2, scleral pigmentation2, subconjunctival cyst2,abnormal sensation in eye1, asthenopia1 Very rare: uveitis3, miosis3 Not known: visual disturbances2, madarosis2 Ear and labyrinth disorders Uncommon: vertigo1, tinnitus2 Cardiac disorders Uncommon: cardio-respiratory distress2, angina pectoris2, arrhythmia3, palpitations2,3, heart rate irregular2, bradycardia2,3, tachycardia3 Vascular disorders Uncommon: hypotension1 Very rare: hypertension3 Respiratory, thoracic and mediastinal disorders Uncommon: dyspnoea2, bronchial hyperactivity2, pharyngolaryngeal pain2, dry throat1, cough2, epistaxis2, upper respiratory tract congestion2, nasal congestion1, rhinorrhoea2, throat irritation2, nasal dryness1, postnasal drip1, sneezing2 Not known: asthma2 Gastrointestinal disorders Common: dry mouth1 Uncommon: dyspepsia1, oesophagitis2, abdominal discomfort1, diarrhoea2, vomiting2, nausea2, frequent bowel movements2, flatulence2, hypoaesthesia oral2, paraesthesia oral1 Hepatobiliary disorders Not known: liver function test abnormal2 Skin and subcutaneous tissue disorders Uncommon: dermatitis contact1, urticaria2, rash2, rash maculopapular2, pruritus generalised2, alopecia2, skin tightness2 Not known: Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) (see section 4.4), face oedema3, dermatitis2,3, erythema2,3 Musculoskeletal and connective tissue disorders Uncommon: back pain2, muscle spasms2, myalgia2 Not known: arthralgia2, pain in extremity2 Renal and urinary disorders Uncommon: renal pain2 Not known: pollakiuria2 Reproductive system and breast disorders Uncommon: erectile dysfunction2 General disorders and administration site conditions Uncommon: pain2, chest discomfort2, feeling abnormal2, feeling jittery2, irritability2, medication residue1 Not known: chest pain2, peripheral oedema2,3 1 adverse reaction observed with SIMBRINZA 2 additional adverse reaction observed with brinzolamide monotherapy 3 additional adverse reaction observed with brimonidine monotherapy Description of selected adverse reactions Dysgeusia was the most common systemic adverse reaction associated with the use of SIMBRINZA (3.4%). It is likely to be caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal and is mainly attributable to the brinzolamide component of SIMBRINZA. Nasolacrimal occlusion or gently closing the eyelid after instillation may help reduce the occurrence of this effect (see section 4.2). SIMBRINZA contains brinzolamide, which is a sulphonamide inhibitor of carbonic anhydrase with systemic absorption. Gastrointestinal, nervous system, haematological, renal and metabolic effects are generally associated with systemic carbonic anhydrase inhibitors. The same type of adverse reactions attributable to oral carbonic anhydrase inhibitors may occur with topical administration. Adverse reactions commonly associated with the brimonidine component of SIMBRINZA include the development of ocular allergic type reactions, fatigue and/or drowsiness, and dry mouth. The use of brimonidine has been associated with minimal decreases in blood pressure. Some patients who dosed with SIMBRINZA experienced decreases in blood pressure similar to those observed with the use of brimonidine as monotherapy. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

If with SIMBRINZA occurs treatment should be symptomatic and supportive. The patient’s airway should be maintained. Due to the brinzolamide component of SIMBRINZA, electrolyte imbalance, development of an acidotic state, and possible nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels must be monitored. There is very limited information regarding accidental ingestion with the brimonidine component of SIMBRINZA in adults. The only adverse reaction reported to date was hypotension. It was reported that the hypotensive episode was followed by rebound hypertension. Oral s of other alpha-2-agonists have been reported to cause symptoms such as hypotension, asthenia, vomiting, lethargy, sedation, bradycardia, arrhythmias, miosis, apnoea, hypotonia, hypothermia, respiratory depression and seizure. Paediatric population Serious adverse reactions following inadvertent ingestion with the brimonidine component of SIMBRINZA by paediatric subjects have been reported. The subjects experienced symptoms of CNS depression, typically temporary coma or low level of consciousness, lethargy, somnolence, hypotonia, bradycardia, hypothermia, pallor, respiratory depression and apnoea, and required admission to intensive care with intubation if indicated. All subjects were reported to have made a full recovery, usually within 6-24 hours.

Pharmacotherapeutic group: Ophthalmologicals, Antiglaucoma preparations and miotics, ATC code: S01EC54 Mechanism of action SIMBRINZA contains two active substances: brinzolamide and brimonidine tartrate. These two components lower intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT) by suppressing the formation of aqueous humour from the ciliary process in the eye. Although both brinzolamide and brimonidine lower IOP by suppressing aqueous humour formation, their mechanisms of action are different. Brinzolamide acts by inhibiting the enzyme carbonic anhydrase (CA-II) in the ciliary epithelium that reduces the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport across the ciliary epithelium, resulting in decreased aqueous humour formation. Brimonidine, an alpha-2 adrenergic agonist, inhibits the enzyme adenylate cyclase and suppresses the cAMP-dependent formation of aqueous humour. Additionally, administration of brimonidine results in an increase in uveoscleral outflow. Pharmacodynamic effects Clinical efficacy and safety Monotherapy In a 6-month, controlled, contribution of elements clinical study enrolling 560 patients with open-angle glaucoma (including pseudoexfoliation or pigment dispersion component) and/or ocular hypertension who, in the investigator’s opinion, were insufficiently controlled on monotherapy or already on multiple IOP-lowering medicinal products, and who had mean baseline diurnal IOP of 26 mmHg, the mean diurnal IOP-lowering effect of SIMBRINZA dosed twice daily was approximately 8 mmHg. Statistically superior reductions in the mean diurnal IOP were observed with SIMBRINZA compared to brinzolamide 10 mg/ml or brimonidine 2 mg/ml dosed twice daily at all visits throughout the study (Figure 1). Figure 1 Meana diurnal (9 AM, +2 hrs, +7 hrs) IOP change from baseline (mmHg) — Contribution of elements study aLeast squares means derived from a statistical model that accounts for study site, 9 AM baseline IOP stratum, and correlated IOP measurements within patient. All treatment differences (SIMBRINZA versus individual components) were statistically significant with p=0.0001 or less. Mean IOP reductions from baseline at each time point at each visit were greater with SIMBRINZA (6 to 9 mmHg) than monotherapy with either brinzolamide (5 to 7 mmHg) or brimonidine (4 to 7 mmHg). Mean percent IOP reductions from baseline with SIMBRINZA ranged from 23 to 34%. The percentages of patients with an IOP measurement less than 18 mmHg were greater in the SIMBRINZA group than in the Brinzolamide group at 11 of 12 assessments through Month 6 and were greater in the SIMBRINZA group than in the Brimonidine group at all 12 assessments through Month 6. At the +2 h time point (the time corresponding to the morning efficacy peak) for the primary efficacy visit at Month 3, the percentage of patients with an IOP less than 18 mmHg was 68.8% in the SIMBRINZA group, 42.3% in the Brinzolamide group, and 44.0% in the Brimonidine group. In a 6-month, controlled, non-inferiority clinical study enrolling 890 patients with open-angle glaucoma (including pseudoexfoliation or pigment dispersion component) and/or ocular hypertension who, in the investigator’s opinion, were insufficiently controlled on monotherapy or already on multiple IOP-lowering medicinal products, and who had mean baseline diurnal IOP of 26 to 27 mmHg, non-inferiority of SIMBRINZA compared to brinzolamide 10 mg/mL + brimonidine 2 mg/mL dosed concomitantly was demonstrated at all visits throughout the study with respect to mean diurnal IOP reduction from baseline (Table 1). Table 1 Comparison of mean diurnal IOP (mmHg) change from baseline – Non-inferiority study Visit SIMBRINZA Meana Brinzolamide + Brimonidine Meana Difference Meana (95% CI) Week 2 -8.4 (n=394) -8.4 (n=384) -0.0 (-0.4, 0.3) Week 6 -8.5 (n=384) -8.4 (n=377) -0.1 (-0.4, 0.2) Month 3 -8.5 (n=384) -8.3 (n=373) -0.1 (-0.5, 0.2) Month 6 -8.1 (n=346) -8.2 (n=330) 0.1 (-0.3, 0.4) a Least squares means derived from a statistical model that accounts for study site, 9 AM baseline IOP stratum, and correlated IOP measurements within patient Mean IOP reductions from baseline at each time point at each visit with SIMBRINZA or the individual components administered concomitantly were similar (7 to 10 mmHg). Mean percent IOP reductions from baseline with SIMBRINZA ranged from 25 to 37%.The percentages of patients with an IOP measurement less than 18 mmHg were similar across study visits for the same time point through Month 6 in the SIMBRINZA and Brinzolamide + Brimonidine groups. At the +2 h time point (the time corresponding to the morning efficacy peak) for the primary efficacy visit at Month 3, the percentage of patients with an IOP less than 18 mmHg was 71.6% in both study groups. Adjunct therapy Clinical data on the use of SIMBRINZA adjunctive to prostaglandin analogues (PGA) also showed superior IOP-lowering efficacy of SIMBRINZA + PGA compared with the PGA alone. In study CQVJ499A2401, SIMBRINZA + PGA (i.e. travoprost, latanoprost, or bimatoprost) demonstrated superior IOP-lowering efficacy from baseline compared to Vehicle + PGA after 6 weeks of treatment, with between- treatment difference in model-adjusted mean change from baseline in diurnal IOP of -3.44 mmHg (95% CI, -4.2, -2.7; p-value <0.001). Clinical data on the use of SIMBRINZA adjunctive to travoprost-timolol maleate fixed dose combination eye drops, solution also showed superior IOP-lowering efficacy of SIMBRINZA + travoprost-timolol maleate eye drops compared with the travoprost-timolol maleate alone. In study CQVJ499A2402, SIMBRINZA + travoprost-timolol maleate eye drops demonstrated superior IOP-lowering efficacy from baseline compared to Vehicle + travoprost-timolol maleate eye drops after 6 weeks of treatment, with between-treatment difference in model-adjusted mean change from baseline in diurnal IOP of -2.15 mmHg (95% CI, -2.8, -1.5; p-value <0.001). The safety profile of SIMBRINZA in adjunct therapy was similar to that observed with SIMBRINZA monotherapy. There are no efficacy and safety data for adjunct therapy beyond 6 weeks. Paediatric population The European Medicines Agency has waived the obligation to submit the results of studies with SIMBRINZA in all subsets of the paediatric population in the treatment of glaucoma and ocular hypertension (see section 4.2 for information on paediatric use).

Absorption Brinzolamide is absorbed through the cornea following topical ocular administration. The substance is also absorbed into the systemic circulation, where it binds strongly to carbonic anhydrase in red blood cells (RBCs). Plasma concentrations are very low. Whole blood elimination half-life is prolonged (>100 days) in humans due to RBC carbonic anhydrase binding. Brimonidine is rapidly absorbed into the eye following topical administration. In rabbits, maximum ocular concentrations were achieved in less than one hour in most cases. Maximum human plasma concentrations are <1 ng/mL and achieved within <1 hour. Plasma levels decline with a half-life of approximately 2-3 hours. No accumulation occurs during chronic administration. In a topical ocular clinical study comparing the systemic pharmacokinetics of SIMBRINZA administered two or three times daily to brinzolamide and brimonidine administered individually using the same two posologies, the steady-state whole blood brinzolamide and N-desethylbrinzolamide pharmacokinetics were similar between the combination product and brinzolamide administered alone. Likewise, the steady-state plasma pharmacokinetics of brimonidine from the combination were similar to those observed for brimonidine administered alone, with the exception of the twice daily SIMBRINZA treatment group, for which the mean AUC0-12 hours was about 25% lower than that for brimonidine alone administered twice daily. Distribution Studies in rabbits showed that maximum brinzolamide ocular concentrations following topical administration are in the anterior tissues such as cornea, conjunctiva, aqueous humour and iris-ciliary body. Retention in ocular tissues is prolonged due to binding to carbonic anhydrase. Brinzolamide is moderately (about 60%) bound to human plasma proteins. Brimonidine exhibits affinity for pigmented ocular tissues, particularly iris- ciliary body, due to its known melanin binding properties. However, clinical and non-clinical safety data show it to be welltolerated and safe during chronic administration. Biotransformation Brinzolamide is metabolised by hepatic cytochrome P450 isozymes, specifically CYP3A4, CYP2A6, CYP2B6, CYP2C8 and CYP2C9. The primary metabolite is N-desethylbrinzolamide, followed by the N- desmethoxypropyl and O-desmethyl metabolites, as well as an N-propionic acid analogue formed by oxidation of the N-propyl side chain of O-desmethyl brinzolamide. Brinzolamide and Ndesethylbrinzolamide do not inhibit cytochrome P450 isozymes at concentrations at least 100-fold above maximum systemic levels. Brimonidine is extensively metabolised by hepatic aldehyde oxidase, with formation of 2oxobrimonidine, 3-oxobrimonidine and 2,3-dioxobrimonidine being the major metabolites. Oxidative cleavage of the imidazoline ring to 5- bromo-6-guanidinoquinoxaline is also observed. Elimination Brinzolamide is primarily eliminated in urine unchanged. In humans, urinary brinzolamide and Ndesethylbrinzolamide accounted for about 60 and 6% of the dose, respectively. Data in rats showed some biliary excretion (about 30%), primarily as metabolites. Brimonidine is primarily eliminated in the urine as metabolites. In rats and monkeys, urinary metabolites accounted for 60 to 75% of oral or intravenous doses. Linearity/non-linearity Brinzolamide pharmacokinetics are inherently non-linear due to saturable binding to carbonic anhydrase in whole blood and various tissues. Steady-state exposure does not increase in a doseproportional manner. In contrast, brimonidine exhibits linear pharmacokinetics over the clinically therapeutic dose range. Pharmacokinetic/pharmacodynamic relationship(s) SIMBRINZA is intended for local action within the eye. Assessment of human ocular exposure at efficacious doses is not feasible. The pharmacokinetic/pharmacodynamic relationship in humans for IOP- lowering has not been established. Other special populations Studies to determine the effects of age, race, and renal or hepatic impairment have not been conducted with SIMBRINZA. A study of brinzolamide in Japanese versus non-Japanese subjects showed similar systemic pharmacokinetics between the two groups. In a study of brinzolamide in subjects with renal impairment, a 1.6- to 2.8-fold increase in the systemic exposure to brinzolamide and Ndesethylbrinzolamide between normal and moderately renally-impaired subjects was demonstrated. This increase in steady-state RBC concentrations of substance-related material did not inhibit RBC carbonic anhydrase activity to levels that are associated with systemic side effects. However, the combination product is not recommended for patients with severe renal impairment (creatinine clearance <30 mL/minute). The Cmax, AUC and elimination half-life of brimonidine are similar in elderly (>65 years of age) subjects compared to young adults. The effects of renal and hepatic impairment on the systemic pharmacokinetics of brimonidine have not been evaluated. Given the low systemic exposure to brimonidine following topical ocular administration, it is expected that changes in plasma exposure would not be clinically relevant. Paediatric population The systemic pharmacokinetics of brinzolamide and brimonidine, alone or in combination, in paediatric patients have not been studied.

Brinzolamide Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single-dose toxicity, repeated dose toxicity, genotoxicity and carcinogenic potential. Effects in non-clinical reproduction and development toxicity studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use. In rabbits oral, maternally toxic doses of brinzolamide of up to 6 mg/kg/day (261 times the recommended daily clinical dose of 23 µg/kg/day) revealed no effect on foetal development. In rats doses of 18 mg/kg/day (783 times the recommended daily clinical dose), but not 6 mg/kg/day, resulted in slightly reduced ossification of skull and sternebrae of foetuses. These findings were associated with metabolic acidosis with decreased body weight gain in dams and decreased foetal weights. Dose related decreases in foetal weights were observed in pups of dams given 2 to 18 mg/kg/day. During lactation, the no adverse effect level in the offspring was 5 mg/kg/day. Brimonidine Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.

Benzalkonium chloride Propylene glycol Carbomer 974P Boric acid Mannitol Sodium chloride Tyloxapol Hydrochloric acid and/or sodium hydroxide (to adjust pH) Purified water

Not applicable.

2 years. 4 weeks after first opening.

This medicinal product does not require any special storage conditions.

8 mL round, opaque, low density polyethylene (LDPE) bottles with a LDPE dropper tip and white polypropylene screw cap containing 5 mL suspension. Carton containing 1 or 3 bottles. Not all pack sizes may be marketed.

No special requirements for disposal.

Feb. 16, 2026

spc-doc_PLGB 00101-1142.pdf

Bulk SPC upload Feb2026